Work

PROSPER: A phase 3 study of enzalutamide in nonmetastatic (M0) castration-resistant prostate cancer (CRPC) patients.

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.tps5094

Authors: Maha Hussain, Karim Fizazi, Fred Saad, Neal D. Shore, Axel Heidenreich, Mohammad Hirmand, Frank Perabo, Zakaria Khondher, Katharina Modelska, Cora N. Sternberg

Institutions: U-M Rogel Cancer Center, Université Paris-Sud, Institut Gustave Roussy, Centre Hospitalier de l’Université de Montréal, Université de Montréal, Carolina Urologic Research Center, RWTH Aachen University, Medivation, Inc. (United States), Astellas Pharma (United States), Azienda Ospedaliera San Camillo-Forlanini

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2596783640

Cites:

Cited by: 8

Related to: 10